等待開盤 02-10 09:30:00 美东时间
-0.030
-0.11%
Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of Dual-Target RNAi Therapy for Mixed Hyperlipidemia Arrowhead Pharmaceuticals Inc. has announced the initiation of a Phase 1/2a clinical trial for ARO-DIMER-PA, an investigational RNA interference (RNAi) therapeutic being developed for the treatme
01-28 01:02